As the covid-19 pandemic increases MPE ramps up production of medical carts
In the likely event the healthcare system reaches capacity, additional multi-purpose life support equipment carts will be needed. MPE is ready to help.
Milwaukee, WI, March 22, 2020– Midwest Products & Engineering (“MPE-INC” or the “Company”), a leading design and manufacturing partner to healthcare and technology OEMs, is taking action following President Trump’s invocation of the Defense Production Act by increasing production of off-the-shelf preconfigured medical carts for ventilators.
In order to treat the most severe COVID-19 cases, the healthcare system’s capacity is expected to be met. As a result, Emergency ICU centers will be needed in highly affected areas. Without portable medical carts with ventilators configured and positioned for fast-paced functionality and mobility, however, they will be dangerously ill-equipped.
Ventilators are critical in the treatment of the most severe cases of COVID-19 in helping patients to breathe, but without portable carts a hospital lacks the fluidity it needs to maximize its impact on patient care.
“As demand for ventilators surges around the world, we are ramping up medical cart production, and as a medical device equipment manufacturer, MPE is classified as an Essential Business – which means we will remain fully operational in the event a Federal, State, or Local quarantine is mandated.” said Hank Kohl, President & CEO of MPE-INC.
Based in Milwaukee, MPE’s FDA registered factory and quality management systems for the healthcare industry remains fully operational with low risk to supply chain and fulfillment of medical customers’ current demand. Their 200 dedicated employees are working overtime to contribute to the fight against coronavirus.
The health and safety of the nation is MPE’s top priority with the capacity to focus on assisting in the pandemic. Contact MPE now by phone (800)266-1687 or by email. MPE is ready to help.
About MPE-INC
MPE-INC is a leading design and manufacturing partner to healthcare and technology OEMs, leveraging core competencies in product design and engineering, high mix / low volume manufacturing, quality systems and 3PL services. For more than 40 years, MPE has successfully serviced an impressive list of blue-chip medical device and technology OEMs, leveraging a vertically integrated business model that offers its growing customer base “Concept to Completion” solutions. MPE-INC is headquartered in Milwaukee.
FOR MORE INFORMATION:
Rick Zanardo
Respirators of Choice when considering CDC Coronavirus Guidelines
The MAXAIR CAPR combines safety and comfort with a patient-friendly interface
With the World Health Organization (WHO) declaring the coronavirus outbreak a public health emergency of international concern, the Centers for Disease Control (CDC) is advising healthcare workers to observe interim recommendations regarding the 2019 Novel Coronavirus (2019-nCoV). These recommendations include the standard precaution to “…assume that every person is potentially infected or colonized with a pathogen that could be transmitted in the healthcare setting.”
Further, the referenced Standard Precautions specify that “(Healthcare) Personnel entering the room (of a patient with known or suspected 2019-nCoV) should use PPE, including respiratory protection …”
Some of the key issues regarding choice of respirator design include accurate fit during actual working conditions, full face, head, and neck contact and fluid protection, overall comfort and non-interference to HCP while performing all required activities, and the ability to communicate with patients who are likely to be under considerable stress.
MAXAIR CAPR is an excellent solution for these and other concerns. This advanced designed PAPR (Powered Air Purifying Respirator) uniquely integrates the motor, fan, filter, and controlled air flow mechanism in a compact, lightweight Helmet. This eliminates the need for a long breathing tube connected to a belt mounted motor-blower-filter unit, both of which are external to gowning, require more rigorous cleaning procedures, and can restrict HCP maneuverability.
The MAXAIR CAPR Systems are positive pressure, loose fitting PAPRs for particulate contaminants and therefore all configurations do not require fit testing.
The type and level of protection required by the situation are addressed by the available CAPR face and head cover alternatives.
The DLC Cuff is a full-face cover (eyes, nose, mouth) that does not require goggles and provides a high protection factor (APF=25).
Shroud and Hood configurations additionally provide full head and neck coverage for respiratory and contact concerns, and a higher protection factor (APF=1000).
CAPRs newest line of Hoods, 2271PB-07 Single and 2272PB-07 Double, provide additional protection as they meet the requirements of the ASTM F1671 standard test method for resistance of materials used in protective clothing to penetration by blood-borne pathogens.
Each CAPR configuration provides HCP with a full, clear field of view and allow full patient communication that includes unobstructed friendly, comforting and reassuring facial expressions.
All MAXAIR PAPRs are NIOSH approved and include a safety LED ESLI (End of Service Life) indicator for both air flow and battery charge in the wearer’s upper peripheral vision, always on and visible during working conditions.
The combination of the LED heads up display, the constant flow air controller that is user adjustable to meet individual cooling vs work exertion needs, and the choice of an 8-10 hour or a 12-15 hour Lithium Ion Battery, assures that HCP can work through a full shift in comfort and without worry.
MAXAIR Systems are backed by a full warranty, on-site and teleconference live training, and a full complement of downloadable training videos and Users Instructions.
MAXAIR Systems have become the respirators of choice for many healthcare organizations looking to augment or upgrade their respiratory protection equipment in the face of this current coronavirus outbreak.
PercuVision and LocumTenens.com Partner to Offer Teleurology Services in Underserved Areas
COLUMBUS, OHIO AND ALPHARETTA, GEORGIA (PRWEB) JANUARY 27, 2020
PercuVision® LLC, developer of the leading integrated telemedicine platform, the DirectVision® DVS-III Telehealth Hub, announced today it has partnered with LocumTenens.com, a prominent physician and advanced practitioner staffing agency, in a pilot program to provide clinical and emergency tele-urology services across the United States. The partnership is expected to improve access to care by extending urology services to urban and rural areas where there are few or no urologists.
According to an American Urology Association survey, the shortage of urology specialists is particularly acute compared with other specialties, with 62 percent of counties in the United States having no practicing urologists. The partnership addresses this pressing need by expanding the geographic practice areas of urologists, allowing clinics and primary care facilities to offer a range of urologic services via telehealth.
As a practicing urologist, PercuVision founder Errol Singh, M.D., F.A.C.S. understands that many patients are unable to access a urologist, but this gap in care can be bridged with virtual medical solutions, such as PercuVision’s DirectVision product line when paired with LocumTenens.com’s expertise in providing telemedicine. The DirectVision products were created to improve patient outcomes by advancing the standard of care through the application of vision technology. “Vision should be the first resort, especially for patients at risk for difficult urinary catheterizations, not the last,” said Singh. “With the PercuVision Telehealth Hub and the clinicians staffed by LocumTenens.com, who have a wealth of telehealth expertise, urology services will be available to many more patients in greatly expanded service areas.”
LocumTenens.com’s clinicians help deliver care to more than seven million patients in over 2,400 healthcare facilities nationwide. The staffing agency has a dedicated telehealth division, led by Director Pamela Ograbisz, DNP, FNP-BC, that creates custom-built workflows and optimizes providers’ tele-urology requirements. Non-urologic providers guided by LocumTenens.com urologists using the PercuVision DirectVision Telehealth Hub can manage urology patients with image-guided instruments for a number of urologic examinations and services, including video interventions and catheter placement.
PercuVision’s Telehealth Hub connects patients with specialists through a built-in video conferencing platform, combined with its DirectVision line of accessories, to support a broad range of medical examinations including:
Live video interventions
- Urinary catheterization
- Consultation
- Endoscopy
- ENT
- Dermatology
- Dentistry
Patient Monitoring
- Digital stethoscope
- Blood pressure
- Pulse oximetry
Nebraska, Nevada, New Mexico, Texas and Wyoming are targeted for the pilot study due to the populations and distribution of people who are often many miles from full-service medical centers. The states also provide telehealth parity for reimbursement through their Medicaid programs, or reimbursement at the same rates as in-clinic care. In addition, the states allow out-of-state physicians who have applied for telemedicine permits to practice in their states.
“Access to specialized medical care, particularly within certain regions of the U.S., continues to be a critical issue,” said Chris Franklin, president of LocumTenens.com. “The partnership between PercuVision and LocumTenens.com brings together innovative medical technology, telehealth and specialized staffing solutions in a way that can truly impact people’s lives.”
About PercuVision
PercuVision® LLC's mission is to improve patient care and safety by applying microfiber-optic bundle technology to common global medical procedures. The DirectVision line of products use patented micro-endoscope technologies to bring vision to blind medical devices. More information on the company can be found by visiting http://www.PercuVision.com.
About LocumTenens.com
LocumTenens.com is a full-service healthcare staffing agency, specializing in the temporary placement of physicians, CRNAs, physician assistants and nurse practitioners at healthcare facilities across the United States. As the industry’s most-visited job board, LocumTenens.com helps healthcare organizations connect with the professionals they need to ensure patients have access to quality care. Founded in 1995, LocumTenens.com is part of the Jackson Healthcare® family of companies. Learn more at http://www.locumtenens.com/about.
For LocumTenens.com media inquiries, please contact Brittany Erskine at berskine@gscommuncations.com.
PercuVision® LLC's mission is to improve patient care and safety by applying microfiber-optic bundle technology to common global medical procedures. The DirectVision line of products use patented micro-endoscope technologies to bring vision to blind medical devices. More information on the company can be found by visiting http://www.PercuVision.com.
LocumTenens.com is a full-service healthcare staffing agency, specializing in the temporary placement of physicians, CRNAs, physician assistants and nurse practitioners at healthcare facilities across the United States. As the industry’s most-visited job board, LocumTenens.com helps healthcare organizations connect with the professionals they need to ensure patients have access to quality care. Founded in 1995, LocumTenens.com is part of the Jackson Healthcare® family of companies. Learn more at http://www.locumtenens.com/about.
Nanovis Wins the Global Health & Pharma 2018 Technology Awards
Oct. 23, 2019 – Nanovis today announced that Global Health & Pharma magazine recognized Nanovis as the Best Nanotechnology Driven Implant Company, 2018.
Nanovis is a technology-driven growth company committed to helping surgeons and hospitals achieve excellent fixation and infection outcomes using advanced nanotechnology platforms. Its industry-leading fixation technologies offer surgeons and hospitals the best aspects of fixation, visualization, and durability. Nanovis’ developmental infection technology platforms promise to offer surgeons and hospitals much-needed bactericidal solutions.
“Nanovis is honored to be recognized for the technology award by Global Health & Pharma,” says Nanovis CEO Matt Hedrick. “It validates the progress we’ve made towards our vision of discovering, licensing and launching the best spinal implant technologies for fixation and infection.
Our technology driven approach is creating a lot of energy with our customers and within Nanovis. Sales of our fixation technologies are increasing rapidly, and our next generation technologies are killing virulent and deadly antimicrobial resistant bacteria while still growing bone. This creates tremendous urgency for us to safely and responsibly bring these technologies to patients who can benefit from them. Many of our customer’s work with Nanovis not only because of our fixation technology enhanced spinal implants but also to help support this vision”
Now in its third year, Global Health & Pharma’s Healthcare & Pharmaceutical Awards celebrate the contributions made by organizations and individuals operating within the world’s most vital industries. The awards are given solely on merit.
“It is our desire to reward those who demonstrate dedication to furthering the advancements within healthcare and pharmaceutical services and products,” Katherine Benton, Awards Coordinator said. “For this reason, we have developed a merit-based judging process providing entrants with the opportunity to share their proudest moments, and greatest achievements within the healing arts.”
Since its inception in 2006, Nanovis has been offering spine surgeons a portfolio of spinal implants with the most advanced fixation technology available, providing surgeons the best aspects of fixation, visualization, and durability.
Today, Nanovis is working to add a bactericidal capability to its fixation technologies as well as technology to treat and prevent localized infections, even those caused by some of the most virulent and deadly antibiotic resistant bacteria in the world today.
For information about distribution opportunities, please contact Jeff Shepherd, Vice President of Sales, at jeff.shepherd@nanovistechnology.com.
About Nanovis
Nanovis’ mission is to develop science-enhanced, life-improving technologies. The Company’s patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore® line of interbody fusion devices (deeply porous ti scaffold licensed from Sites Medical); an advanced nano-surface technology in development; a surface technology with anti-colonization and anti-microbial capabilities in pre-clinical studies, and a localized infection technology targeted toward anti-microbial resistant bacteria in pre-clinical studies.
About GHP
GHP is a quarterly magazine brought to you by AI Global Media Ltd., established to enhance communication networks & collaboration across all themes and disciplines within three main categories: Human, Animal & Environmental Health. Its topical news articles make it a valued read, and this readability ensures that advertisers will benefit greatly from their investment.
“Nanovis is honored to be recognized for the technology award by Global Health & Pharma,” says Nanovis CEO Matt Hedrick. “It validates the progress we’ve made towards our vision of discovering, licensing and launching the best spinal implant technologies for fixation and infection.
Our technology driven approach is creating a lot of energy with our customers and within Nanovis. Sales of our fixation technologies are increasing rapidly, and our next generation technologies are killing virulent and deadly antimicrobial resistant bacteria while still growing bone. This creates tremendous urgency for us to safely and responsibly bring these technologies to patients who can benefit from them. Many of our customer’s work with Nanovis not only because of our fixation technology enhanced spinal implants but also to help support this vision”
Now in its third year, Global Health & Pharma’s Healthcare & Pharmaceutical Awards celebrate the contributions made by organizations and individuals operating within the world’s most vital industries. The awards are given solely on merit.
“It is our desire to reward those who demonstrate dedication to furthering the advancements within healthcare and pharmaceutical services and products,” Katherine Benton, Awards Coordinator said. “For this reason, we have developed a merit-based judging process providing entrants with the opportunity to share their proudest moments, and greatest achievements within the healing arts.”
Since its inception in 2006, Nanovis has been offering spine surgeons a portfolio of spinal implants with the most advanced fixation technology available, providing surgeons the best aspects of fixation, visualization, and durability.
Today, Nanovis is working to add a bactericidal capability to its fixation technologies as well as technology to treat and prevent localized infections, even those caused by some of the most virulent and deadly antibiotic resistant bacteria in the world today.
For information about distribution opportunities, please contact Jeff Shepherd, Vice President of Sales, at jeff.shepherd@nanovistechnology.com.
About Nanovis
Nanovis’ mission is to develop science-enhanced, life-improving technologies. The Company’s patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore® line of interbody fusion devices (deeply porous ti scaffold licensed from Sites Medical); an advanced nano-surface technology in development; a surface technology with anti-colonization and anti-microbial capabilities in pre-clinical studies, and a localized infection technology targeted toward anti-microbial resistant bacteria in pre-clinical studies.
About GHP
GHP is a quarterly magazine brought to you by AI Global Media Ltd., established to enhance communication networks & collaboration across all themes and disciplines within three main categories: Human, Animal & Environmental Health. Its topical news articles make it a valued read, and this readability ensures that advertisers will benefit greatly from their investment.
BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients
San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc.
announced the first patient was enrolled and treated in the REVIVE-HF
European study, a prospective multi-center, dual-arm randomized
controlled study evaluating the treatment of ischemic cardiomyopathy
induced heart failure with the Revivent TC™ System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment.
The patient was treated at Deutsches Herzzentrum Berlin (DHZB), Germany and was successfully implanted with three anchor pairs in a patient who suffered a heart attack resulting in scarring in the left ventricle and subsequently developed ischemic heart failure.
Principal investigator for REVIVE-HF, Prof. Volkmar Falk (DHZB), said the enrollment marks a significant milestone validating the Revivent TCTM TransCatheter Ventricular Enhancement System to become an important treatment option for ischemic heart failure with reduced ejection fraction (HFrEF) patients.
“The Revivent TC System for less invasive ventricular remodeling offers patients a treatment option for ischemic heart failure,” says Prof. Falk. “We lead this trial in Europe as the Revivent TC System has the ability to address the underlying cause of heart failure in heart attack victims, the ventricle. The device can provide substantial volume reduction and exclusion of scar tissue to help remodel the ventricle to become more efficient.”
The Revivent TC System offers patients with abnormally dilated hearts the benefits of reducing the dilated heart by less invasively excluding scar (dead tissue) from the healthy tissue on the left ventricle with its anchoring technology. The result is decreased systolic volume providing increased efficiency of the left ventricle.
“A critical parameter to survival for these types of patients is cardiac volume,” says Prof. Sebastian Kelle, Cardiologist at DHZB. “We were able to see an immediate impact of around 40% volume reduction resulting in an 36% to 43% increase in ejection fraction for the patient that was treated in the REVIVE-HF trial. We have seen from our previous commercial experience in the last two years that these types of numbers have significantly changed the quality of life of patients who suffer from ischemic left ventricular dysfunction. We are proud to be the first center to enroll in this study.”
The REVIVE-HF RCT (NCT03845127) plans to enroll 180 patients with 120 patients to be treated with the Revivent TC System and 60 patients will be maintained on GDMT. Its primary endpoint is improvement in heart failure symptoms based on a 6 Minute Walking Test. The Revivent TC System is intended for use in patients who have had a myocardial infarction (MI) (heart attack), creating a left ventricular scar, resulting in an enlarged left ventricle causing heart failure symptoms. These symptoms include fatigue, shortness of breath and/or physical limitations despite ongoing treatment.
About BioVentrix
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.
Less Invasive Ventricular Enhancement or the LIVE ™ procedure uses the Revivent TC™ Transcatheter Ventricular Enhancement System to exclude the scar tissue on the left ventricle that has occurred from a heart attack. This is achieved by implanting anchor pairs on the scar along the septum of the right ventricle and outer surface of the left ventricle. Excluding the scar tissue allows the remaining functional healthy tissue of the left ventricle to operate more efficiently. The implant will help remodel the heart back to a more regular shape and size resulting in an improvement in blood flow throughout the body and benefit the rest of the organs.
WATCH ONE PATIENT’S STORY
Current Clinical Trials
Europe: REVIVE-HF & USA: ALIVE
Note: The Revivent TCTM System is approved for sale in Europe; it is not approved for sale in the United States, but a licensing study is ongoing.
# # # # #
Contact: Nicholas Corso, Director, Marketing, +1-925-830-1000.
The patient was treated at Deutsches Herzzentrum Berlin (DHZB), Germany and was successfully implanted with three anchor pairs in a patient who suffered a heart attack resulting in scarring in the left ventricle and subsequently developed ischemic heart failure.
Principal investigator for REVIVE-HF, Prof. Volkmar Falk (DHZB), said the enrollment marks a significant milestone validating the Revivent TCTM TransCatheter Ventricular Enhancement System to become an important treatment option for ischemic heart failure with reduced ejection fraction (HFrEF) patients.
“The Revivent TC System for less invasive ventricular remodeling offers patients a treatment option for ischemic heart failure,” says Prof. Falk. “We lead this trial in Europe as the Revivent TC System has the ability to address the underlying cause of heart failure in heart attack victims, the ventricle. The device can provide substantial volume reduction and exclusion of scar tissue to help remodel the ventricle to become more efficient.”
The Revivent TC System offers patients with abnormally dilated hearts the benefits of reducing the dilated heart by less invasively excluding scar (dead tissue) from the healthy tissue on the left ventricle with its anchoring technology. The result is decreased systolic volume providing increased efficiency of the left ventricle.
“A critical parameter to survival for these types of patients is cardiac volume,” says Prof. Sebastian Kelle, Cardiologist at DHZB. “We were able to see an immediate impact of around 40% volume reduction resulting in an 36% to 43% increase in ejection fraction for the patient that was treated in the REVIVE-HF trial. We have seen from our previous commercial experience in the last two years that these types of numbers have significantly changed the quality of life of patients who suffer from ischemic left ventricular dysfunction. We are proud to be the first center to enroll in this study.”
The REVIVE-HF RCT (NCT03845127) plans to enroll 180 patients with 120 patients to be treated with the Revivent TC System and 60 patients will be maintained on GDMT. Its primary endpoint is improvement in heart failure symptoms based on a 6 Minute Walking Test. The Revivent TC System is intended for use in patients who have had a myocardial infarction (MI) (heart attack), creating a left ventricular scar, resulting in an enlarged left ventricle causing heart failure symptoms. These symptoms include fatigue, shortness of breath and/or physical limitations despite ongoing treatment.
About BioVentrix
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.
Less Invasive Ventricular Enhancement or the LIVE ™ procedure uses the Revivent TC™ Transcatheter Ventricular Enhancement System to exclude the scar tissue on the left ventricle that has occurred from a heart attack. This is achieved by implanting anchor pairs on the scar along the septum of the right ventricle and outer surface of the left ventricle. Excluding the scar tissue allows the remaining functional healthy tissue of the left ventricle to operate more efficiently. The implant will help remodel the heart back to a more regular shape and size resulting in an improvement in blood flow throughout the body and benefit the rest of the organs.
WATCH ONE PATIENT’S STORY
Current Clinical Trials
Europe: REVIVE-HF & USA: ALIVE
Note: The Revivent TCTM System is approved for sale in Europe; it is not approved for sale in the United States, but a licensing study is ongoing.
# # # # #
Contact: Nicholas Corso, Director, Marketing, +1-925-830-1000.
OrthoMed, Inc. Introduces Re-Usable Nitinol Spinal Trial Rods That Offer Flexibility and StrengthSilicone covered memory metal offers multi-use trial rods for lumbar fixation
TIGARD, ORE. (PRWEB) SEPTEMBER 25, 2019
OrthoMed Inc. today announced the addition of multi-use nitinol trial rods for spine surgery to its surgical instrumentation catalog.
OrthoMed’s innovative multi-use flexible silicone trial rods with nitinol wire center relax when they’re autoclaved, returning the rod to its original shape. The new memory metal nickel titanium offers unmatched flexibility and strength for use in a shape memory alloy-assisted correction rod for scoliosis and other lumbar fixation applications.
The strength combined with flexibility of nitinol makes these silicone-covered trial rods the solution of choice for surgeons seeking ease of use and superior precision with lumbar correction of spinal deformities or degeneration such as lumbar spondylolisthesis or degenerative disc disease.
The greater ease of use can result in shorter fitting times and superior positioning precision, which can reduce total surgery time and blood loss.
The nitinol memory alloy is characterized by its malleability at low temperatures and its ability to return to a preconfigured shape above its activation temperature allowing multiple use of these correction tools after autoclaving.
"Orthomed has an outstanding track record at providing hospitals and OEMs with innovative solutions to their instruments and implants needs", said Ron Dyches, President. "The addition of the nitinol rods to our extensive product offering demonstrates our relentless commitment to continuously improving efficiency and clinical outcomes in spine surgery.”
OEM’s adding the OrthoMed multi-use flexible silicone trial rods are leading the market in providing an advanced solution to surgeons frustrated by current trial rods. OrthoMed offers standard off-the-shelf or custom lengths, available in your company logo colors.
See for yourself the advantages of multi-use flexible silicone trial rods with nitinol at NASS September 25-27, 2019. OrthoMed will be exhibiting its full range of surgical instrumentation at Booth #5211.
About OrthoMed, Inc.
OrthoMed has been providing healthcare professionals quality products and services since 1970. Founded by Ronald E. and Martha Dyches who built a successful business on the values of bringing innovative products to the market and providing the highest level of service possible.
OrthoMed continues that commitment today, providing healthcare professionals with the highest quality products and services at the most competitive prices. As surgical instrument specialists OrthoMed offers one of the largest selections of orthopedic and spinal instruments.
All its surgical instruments featured in the OrthoMed catalog are made of the highest-grade German stainless steel and are crafted to rigorous and exacting standards. We demand from our instrument makers: precision and reliability, consistency of pattern, and uniform surface.
For more information about OrthoMed, please contact:
Ronald Dyches, President
Tel: 1-800-547-5571
Ron@orthomedinc.com
http://www.orthomedinc.com
Ronald Dyches, President
Tel: 1-800-547-5571
Ron@orthomedinc.com
http://www.orthomedinc.com
Canada to Key West Campaign Spotlights the Impact of Extreme Weather on People with Disabilities
Canada to Key West, a 2,350-mile walk to raise awareness about the impact of increasingly frequent extreme weather events on persons with physical and cognitive disabilities, will kick off on June 21, 2019, the day of the summer solstice.
The campaign, which is co-sponsored by the Association of Academic Physiatrists (AAP), will raise funds to benefit United Spinal Association and bring greater resources and support to people with disabilities that are affected by extreme weather events.
An estimated one in five people lives with a disability today. These individuals are more vulnerable during extreme weather events and their aftermath. It can be difficult to impossible for someone with a disability to evacuate during a disaster.
Canada to Key West co-founders, Drs. Marcalee and Craig Alexander, will walk the 2,350-mile route to rehabilitation hospitals along the way in Boston, New York City, Philadelphia, Washington D.C., Richmond and Charleston to engage with academic partners about the need for more effective mechanisms and planning to help people with disabilities during extreme weather events, such as hurricanes, floods, polar vortices and heat waves.
“I find it terrible that you can find hundreds of pictures of pets being rescued in floods or hurricanes, but you never see the person in the wheelchair, because often, they are not saved,” says Marcalee Alexander, MD.
“Moreover, polar bears are considered the symbol of climate change, and we don’t acknowledge that people with disabilities are being affected now. I want to find the unsung heroes with disabilities that have faced extreme weather disasters, so they can tell their stories,” adds Alexander.
The Canada to Key West walk will begin on historic Campobello Island, New Brunswick, Canada, where former U.S. President Franklin Delano Roosevelt had a summer home. Pres. Roosevelt contracted polio as a young man and spent the remainder of his life with paralysis; he was a strong advocate for rehabilitation research. The walk will continue through major cities on the East Coast, ending in Key West, Florida.
Along the walk, participants would like to bring together government, academic and community members together to discuss communications and response plans to aid people with and without disabilities during extreme weather events.
The goal is to forge new partnerships between consumers with and without disabilities, academicians and clinicians that care for persons with disabilities to address how extreme weather is impacting people now and what we need to do in order to decrease further mishaps.
In addition, local community members are asked to join the quest, walk or roll in conjunction with participants, mayors’ offices on disabilities, and community groups.
The mission of Canada to Key West was recently highlighted in a session on climate change and its potential impact on people with disabilities at the AAP Annual Meeting in Puerto Rico.
Puerto Rico was devasted by Hurricane Maria in 2017, and thousands of citizens were left without power, clean water, medical supplies and access to medical services for months. Puerto Ricans with disabilities were the most vulnerable of all during the disaster and its aftermath.
For more information on supporting or participating in the Canada to Keywest walk, visit www.canadatokeywest.org. You can also follow developments on the campaign’s social media pages on Facebook, Twitter or Instagram.
ControlRad™ Announces FDA Clearance and Launch of the Only Radiation Reduction Technology that Integrates into Mobile C-arms
- ControlRad
- Press Release
The ControlRad Trace solution reduces unnecessary radiation up to 89%, protecting patients and medical staff without compromising image quality or workflow. 1
ATLANTA, May 22, 2019 -- ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures, today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its ControlRad Trace and the company has initiated its commercial launch. The ControlRad Trace is the only technology that can be integrated into existing mobile C-arms to reduce radiation in any fluoroscopic imaging procedure.
“Radiologists and our teams have grave concerns about the long-term effects from radiation exposure,” said John A. Carrino, M.D., M.P.H. , vice chairman of Radiology, Hospital for Special Surgery. “I am excited that new technology for mobile C-arms is now available because it has the potential to drastically improve our radiation safety while maintaining image quality so we can continue to effectively diagnose and treat our patients. I believe these new products should become the standard of care for fluoroscopic procedures.”
Fluoroscopically guided procedures (FGP) with C-arms have allowed for major advances in treating countless diseases, however they expose patients and medical staff to ionizing radiation, which may increase a person’s lifetime risk of developing cancer.2 For example, an interventional fluoroscopy procedure is roughly equivalent to the adult effective dose of between 250-3,500 chest X-rays.3
“Radiation from C-arm procedures may increase the risk of brain cancer, cataracts, strokes and atherosclerosis,” says Guillaume Bailliard, ControlRad chief executive officer. “It’s our mission to dramatically reduce these life-altering radiation health risks to medical personnel and patients. This FDA clearance for ControlRad Trace allows us to provide our valuable radiation reduction technology to all mobile C-arm users looking to provide a safer environment without compromising patient care.”
With its proprietary semi-transparent filter, tablet and image processing technology, the ControlRad Trace solution can be retrofitted on existing C-arms, reducing the barrier to adopting the technology in order to reduce unnecessary radiation up to 89%,1 without compromising image quality in the region of interest and overall workflow. The medical staff draws a region of interest (ROI) on a ControlRad tablet, which in real-time optimizes image quality in the ROI while reducing unnecessary radiation in the periphery.
“With over 17 million fluoroscopic procedures in the U.S. every year, the ControlRad Trace is the only system available that can impact all of them,” says Chris Fair, ControlRad executive vice president and president, Mobile C-arm division. “Regardless if it is a pain management treatment, an orthopedic trauma case or even a minimally invasive spine procedure, our technology will reduce radiation exposure and protect those who are saving the lives of others.”
ControlRad is now initiating the commercialization of ControlRad Trace. To learn more about ControlRad Trace, visit www.ControlRad.com or email info@ControlRad.com.
References
1 Data on file
3 Ibid, p. 3
About ControlRad
ControlRad is a privately held medical technology company developing innovative products that dramatically reduce the radiation exposure from fluoroscopically guided procedures (FGP) for patients and healthcare professionals. ControlRad’s products are designed to improve safety without compromising image quality or workflow. They include an integrated set of proprietary components, which optimize the X-ray beam to deliver optimal image quality in the clinically relevant region while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Atlanta, Georgia, and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.
Former United States Secretary of the VA, David Shulkin, Joins ControlRad Board of Directors
David Shulkin's experience in running healthcare systems makes the appointment a strategic addition as ControlRad moves into a commercial phase.
PHILADELPHIA, PA, January 30, 2019 – ControlRad, a medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from imaging procedures, today announced changes to its Board of Directors.
Amir Yaron, PhD will be stepping down from the ControlRad Board of Directors due to his appointment as the Governor of the Israeli Bank. Taking his place is David Shulkin, MD, former United States Secretary of the Veterans Affairs. The stature and prestige of these two leaders speaks to the quality of the ControlRad Board of Directors.
“We will miss the valued contributions of Amir to our company’s Board of Directors, and fully appreciate why Prime Minister Netanyahu appointed him as Governor of the Israeli Bank,” said Guillaume Bailliard, President and CEO, ControlRad. “At the same time, we are thrilled that David has rejoined our board. His experience in leading healthcare systems will bring tremendous value to the company as we move into a commercial phase.”
Dr. Shulkin has long been a leader in healthcare management and policy having spent much of his professional career advancing patient safety and quality in healthcare. At the VA, Dr. Shulkin headed the largest integrated healthcare system in the United States, providing care at 1,250 health care facilities, including 172 VA Medical Centers and 1,069 outpatient sites of care.
In the private sector, he served as the President and Chief Executive Officer of Beth Israel Medical Center in New York City, and as Chief Medical Officer of the University of Pennsylvania Health System, the Hospital of the University of Pennsylvania, Temple University Hospital, and the Medical College of Pennsylvania Hospital. Dr. Shulkin has also served as Chairman of Medicine and Vice Dean at Drexel University College of Medicine, and Professor of Medicine at Albert Einstein College of Medicine.
A board-certified internist, Dr. Shulkin is also a Fellow of the American College of Physicians. He received his medical degree from the Medical College of Pennsylvania and completed his internship at Yale University School of Medicine and a fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He also received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania.
Modern Healthcare named Dr. Shulkin as one of the “50 Most Influential Physician Executives in the Country” in 2017.
ControlRad is a privately held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components, which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit https://www.controlrad.com.
MYOLYN and YMCA Team Up to Provide Therapeutic Exercise to People with Disabilities
YMCA Receives New MyoCycle Therapy System to Help Locals with Disabilities
Gainesville, FL – December 27, 2017 – MYOLYN, a medical technology company dedicated to improving health and human performance, announced today that the YMCA in Batavia, NY has purchased the MyoCycle Pro FES cycling therapy system for its members with neurological disabilities.
The MyoCycle Pro uses Functional Electrical Stimulation (FES)technology to allow disabled individuals to exercise and maintain a healthier lifestyle.
“The MyoCycle Pro FES bike is essentially a stationary exercise cycle that someone who is paralyzed can use because it activates their muscles for them,” says MYOLYN co-founder and CTO, Matt Bellman. “The result is a device that allows people with paralysis to achieve load-bearing exercise that is both therapeutic and enjoyable.”
Ricky Palermo, 57, experienced a C5 spinal injury in a 1981 car accident. After his injury, he underwent rehabilitation at the Miami Project to Cure Paralysis. Since then, he has run an annual golf tournament in his hometown of Batavia, NY, as a fund-raiser for the Miami Project and two local hospitals and the YMCA. It was through a research projectconducted by Mark Nash, PhD, FACSM, at the Miami Project that Palermo first heard about the MyoCycle.
In the past, Palermo donated his own FES bike to the Batavia YMCA for others to use. Two years ago, he proposed a new FES bike for the YMCA and raised money for the project, ultimately replacing the old one. This year, they decided that they needed a second FES bike to keep up with demand. Nash recommended that they get a MyoCycle, so Palermo and other YMCA patrons raised money to purchase a MyoCycle Pro. Palermo says they now have a group of five members who use the machines three days a week.
The reason they chose the MyoCycle was simple. “There aren’t too many bikes like this, this is a unique FES bike…other FES cycles cost around $30,000. The MyoCycle is more advanced and less than half that [price],” Palermo says.
Megan Boring, Aquatics & Healthy Heart Coordinator at the Batavia YMCA says the MYOLYN technology makes the MyoCycle Pro the choice for a fitness center.
“One of the reasons the YMCA chose the MyoCycle Pro is that MYOLYN’s technology offers a system that automatically customizes the FES for the individual patient, reducing the need for a trained specialist,” she says. “It makes set-up and installation simple and affordable. It allows us to extend our core mission at the YMCA to provide a caring and inclusive place for everyone regardless of ability.”
“One of MYOLYN’s missions is making FES cycling technology available to all the people that can benefit from it,” says Alan Hamlet, MYOLYN co-founder and CEO. “Working with the YMCA is a big step towards achieving that mission. Now that the GLOW YMCA has a MyoCycle FES cycling therapy system, people with disabilities from the community can obtain therapeutic exercise to help maintain their health and physical well-being.”
The MyoCycle is intended for general rehabilitation for:
- Relaxation of muscle spasms
- Prevention of muscle atrophy
- Increasing local blood circulation
- Maintaining or increasing range of motion
Anyone interested in learning more about the MyoCycle and the team behind it should visit the MYOLYN website at www.MYOLYN.com or contact the team at myolyn@myolyn.com
About MYOLYN
MYOLYN’s vision is to improve health and human performance by empowering people to move. Located in Gainesville, FL, MYOLYN was founded in 2013 by founders Alan Hamlet and Matthew Bellman, both of whom received their PhD’s in robotics from the University of Florida. MYOLYN uses its unique expertise in automation to develop electrical stimulation devices that are innovative, affordable, and easy-to-use.
About YMCA
As a branch of the GLOW YMCA, the Genesee County YMCA serves youth, teens, families, adults and seniors in Genesee County. At the YMCA we welcome and support children and families and help build the values of caring, honesty, respect and responsibility. The YMCA is here for everyone, people of all ages, races, religions, incomes and abilities. The YMCA builds community and welcomes everyone regardless of their ability to pay.
Molecular Matrix, Inc. Receives a 510K Clearance for its Revolutionary
Bone Graft Substitute Technology, Osteo-P™
Exceptional resorption profile earns FDA nod
SACRAMENTO, CALIF. (PRWEB) JANUARY 17, 2018
Bone marrow-derived stem and progenitor cells on Osteo-P™ |
Molecular Matrix, Inc (MMI) today announced the FDA clearance (510k) of Osteo-P™, a value-driven, effective musculoskeletal solution for bone regeneration.
The Osteo-P™ bone graft substitute is a non-mineralized, synthetic bone void filler made of a hyper-crosslinked carbohydrate polymer (HCCP). It is highly porous, biocompatible, biodegradable, and has shown exceptional capabilities of bone repair.
The polymer technology offers several advantages over current bone graft substitutes, including exceptional bone formation and implant resorption, real-time fusion monitoring, and the ability to hold a suture.
Based on proprietary research, Osteo-P™ is intended for the filling of bone defects created surgically or through traumatic injury. When placed or gently packed into bone voids, Osteo-P™ supports and guides the ingrowth of new bone across the graft site, after which it is resorbed and replaced by newly formed bone during the healing process.
“Osteo-P™ provides an optimal microenvironment for infiltration of bone precursors such as osteoblasts that have been known to play a key role in bone regeneration,” says Molecular Matrix founder and CEO Charles Lee, PhD. “This microenvironment includes a significant surface area that allows the flow of fluids and metabolites, leading to the formation of healthy bone.”
The product is available in large pore granules, sheets, cubes, wedges and cylinders offering greater application, flexibility, and excellent handling characteristics. Additionally, customized products are routinely manufactured for collaborative research projects and may be useful for complex anatomic defects.
“The compressibility and tensile strength of Osteo-P™ allows the scaffold to be gently packed in to fill a void.” says Kee D. Kim, MD, Professor of Neurological Surgery and Co-Director of the University of California Davis Health, Spine Center. “The degradation profile, in conjunction with host bone regeneration, results in the formation of the patient's own healthy bone.”
Osteo-P™ is intended for single patient use only, and is provided in a one-time use, with double sterile packaging. It is not indicated for use as a structural support in load bearing applications. The technology is delivered in a ready to use sterile package, and stores at room temperature. Additionally, Osteo-P™ is not subject to degradation through hydrolysis, making shipping logistics more convenient.
“The Osteo-P™ bone void filler provides cutting edge technology for our sales channels, offering significant advantages over other bone void fillers in the market today. In addition, this technology platform ensures Molecular Matrix will continue to develop this technology for multiple other tissue regeneration initiatives and other specific clinical applications” states Jim Keefer, COO of Molecular Matrix. “We are all very excited about our future, and expect significant market penetration over the coming months and years.”
Molecular Matrix’s HCCP technology provides a broad platform for tissue engineering in the orthopedic disciplines. Its HCCP has been shown to be effective for bone regeneration, evidenced by bone precursor cell activities. The technology will bring advancements in orthopedics, spine, trauma, and dental applications with superior bone regeneration products.
MMI has assembled a strong management team and Board of Directors (BOD) and believes that the quality and experience of the group is a critical factor to the success of the Company. MMI’s management team and BOD have over 75 years of experience in research and development, spine and biologics, and commercialization of new technologies.
PARCA adds new DICOM certification
APRIL 1, 2017 – The PACS Administrators Registry and Certification Association (PARCA) announced today that it is adding a certification and certification exams for DICOM, the international standard for Digital Imaging and Communications in Medicine. The new certification will replace the Certified PACS Interface Analyst (CPIA) certification.
Since the National Electrical Manufacturers Association (NEMA) first introduced the DICOM standard in 1985, it has grown both in acceptance and complexity with the adoption of a number of changes and the development of DICOM extensions. As a result Charles Wills, PhD, DABR, president of PARCA says it is time to add a certification that more specifically focuses on DICOM.
“DICOM, the international standard for digital imaging communications in medicine was established by the DICOM committee, an International Standards Organization (ISO). It is really the foundation for understanding how all the parts of a PACS system work together,” Willis says. “You could be very well-educated in computer science or knowledgeable about information technology, but unless you know DICOM, you don’t know how the Open Systems Interconnection (OSI) standard is implemented in imaging informatics.”
The new DICOM certification and the exams supporting it have been updated to cover the breadth and depth of the DICOM standard including the latest extension, DICOMweb. These exams will continue to be updated every three years. Taking the updated exams every three years will replace previous requirements for members to submit 60 hours of continuing education and to re-take the exam every 5 years to maintain certification.
The new certification also is acknowledgement of the evolution of image archiving and communications within medical institutions and the adoption of the standard by professionals outside of radiology who are being drawn together to implement EMRs and enterprise wide vendor neutral archives, according to PARCA founder Herman Oosterwijk.
“There are a number of people who are not in radiology, who all know what DICOM is, but there are a lot of new applications that are starting to use DICOM, all the ‘ologies,’ ophthalmology, cardiology, dermatology. In addition there is a lot of excitement around DICOMweb that will be essential for archiving and sharing visible light medical imaging among medical professionals that need to be a part of the PACS or IT administrator’s toolkit,” Oosterwijk says. “It will be good for these people to acquire the necessary knowledge in an organized and methodical manner to ensure the integrity of the standard as it is implemented in all these new settings. Consequently we felt there is a need for this certification focusing on DICOM so that people will know how to study it and learn about it.”
The new certification along with the study guide for the exam became available on April 1, 2017 and the new certification course is available online through Examity, which provides virtual monitoring testing administered by Examity, thus eliminating having to travel for the exam. Those who previously earned the CPIA certification will have an opportunity to update their knowledge and earn the DICOM certification at a significant discount.
“The DICOM Certification would be worthwhile for anyone wanting to demonstrate external acknowledgement of achievement of a level of proficiency in the DICOM standard,” says Willis. “These might include PACS analysts, healthcare informatics software developers, medical device integration engineers, medical device service engineers, radiologic technologists, or medical physicists.”
ABOUT PARCA
PARCA is an international, USA-based non-profit organization, providing qualified certification programs for health care imaging and IT professionals in the PACS and EMR field. Its board of directors has representation from the USA, Canada, Australia and Singapore. For more information on PARCA, contact executive secretary Kirstin Leal at info@pacsadmin.org
I have recently started a blog, the info you provide on this site has helped me greatly. Thanks for all of your time & work. Superior court
ReplyDelete